在阿尔茨海默氏病中,TRPC3抑制改善了突触功能障碍和记忆缺陷
bioRxiv : the preprint server for biology
|September 30, 2024
概括
在阿尔茨海默氏症 (AD) 中,暂时受体潜在的3 (TRPC3) 通道被上调,导致过载和神经毒性. 用JW-65抑制TRPC3通过恢复突触功能为AD提供了一个有希望的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 暂时受体潜在规范 (TRPC) 通道在神经退行,特别是阿尔茨海默病 (AD) 中的作用尚未完全理解.
- 在AD患者队列和模型中,TRPC3基因表达在刺激神经元中升高.
研究的目的:
- 为了研究TRPC3在AD病变发生过程中的作用.
- 确定和评估TRPC3作为AD的治疗点.
主要方法:
- 来自AD患者的单细胞RNA-seq数据的生物信息分析.
- 在死后AD大脑和AD小鼠模型中评估TRPC3表达.
- 对TRPC3抗剂的功能查,识别JW-65.
- 在体外研究中使用培养的老鼠海马神经元,用粉样β oligomers (AβOs) 治疗.
- 在AD模型中评估JW-65在拯救AβO诱导的神经毒性,突触可塑性缺陷和记忆障碍方面的疗效.
- 分析信号通路和下游效应器 (CaMKII/IV,尿素).
- 来自接受JW-65治疗的5xFAD小鼠的海马组织的RNA-seq分析.
主要成果:
- 在AD的激发性神经元中,TRPC3具有独特的上调.
- 在AD大脑和实验模型中,TRPC3表达增加.
- 作为TRPC3抑制剂的JW-65,在AD模型中完全逆转了Aβ诱导的神经毒性,突触功能障碍和记忆缺陷.
- AβO诱导TRPC3上调,导致通过进入和储存释放而过载.
- JW-65恢复了AβO受损的Ca2+/calmodulin介导的信号通路.
- 在5xFAD小鼠中,JW-65治疗改善了突触功能.
结论:
- TRPC3是AD中突触功能障碍的验证治疗标.
- 升级的TRPC3通过调解二氧化稳定作用,在AD的发病过程中起着至关重要的作用.
- 抑制TRPC3为阿尔茨海默病提供了一种新的治疗途径.
相关概念视频
Role of Neurotransmitters in Memory
466
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
466
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Long-term Potentiation
2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.7K


